Orbis Medicines Raises EUR 90 Million Series A Funding Round to Develop Pipeline of Oral Macrocycles [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Orbis' n Gen platform systematically explores oral macrocycle design with automated chemistry and machine learning Financing led by NEA with new investors Lilly Ventures, Cormorant, the Export and Investment Fund of Denmark and founding investors Novo Holdings and Forbion Morten Graugaard appointed Chief Executive Officer COPENHAGEN, Denmark, January 06, 2025 BUSINESS WIRE )--Orbis Medicines, a leader in oral macrocycle drug discovery, today announces the close of a EUR 90 million Series A funding round, bringing the total amount raised by the company to EUR 116 million. The funds will support the development of Orbis' pipeline of next-generation oral macrocycle drugs, called ‘ n Cycles.' This financing was led by NEA (New Enterprise Associates) with participation from new investors including Eli Lilly and Company, Cormorant, the Export and Investment Fund of Denmark and founding investors Novo Holdings and Forbion. Morten Graugaard has been named the Chief Executive Officer of
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Lilly to participate in J.P. Morgan Healthcare ConferencePR Newswire
- The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer [Yahoo! Finance]Yahoo! Finance
- Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst [Yahoo! Finance]Yahoo! Finance
- Weight loss drugs are changing the game, Eli Lilly exec says — but many still can't get them [Yahoo! Finance]Yahoo! Finance
- Lilly’s Obesity Drug Zepbound To Be Key 2025 Health Cost Driver [Forbes]Forbes
LLY
Earnings
- 10/30/24 - Miss
LLY
Sec Filings
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- 12/17/24 - Form 4
- LLY's page on the SEC website